Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.
Also called NCT03798080
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 426 participants
- Sponsor
- Registry
-
NCT03798080
-
- Other papers using this trial's data
- iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03798080. Randomized; no masking; primary purpose treatment. Start 2019-02-19 (actual); primary completion 2020-12-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
- Acronym
- Lixilan-L-CN
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03798080- Content hash
fe10bf68c64b73605bb70368a51eeb19f7a00b5bfc419f355a1e3ed6d080eba2